Moderna Therapeutics raises millions in the biggest biotech private round

0
962

Moderna Therapeutics, a biotechnology company in Cambridge, Massachusetts, has raised a whopping $ 450 million from investors in the biggest Biotech Private round ever. The investors include Viking Global Investors LP, Invus, RA Capital Management, and Wellington Management Company, LLP, AstraZeneca and Alexion Pharmaceuticals. Other companies that raised large amounts of money in the past years are Inatarcia Therapeutics of Hayward, California ($210 million), Seattle immunotherapy’s startup Juno Therapeutics ($175 million) and Pacific Biosciences ($109 million). But Moderna Therapeutics has beat them all in the money-raising department. In total, it has raised a staggering $950 million, including the money it received as upfront payments from AstraZeneca ($240 million) and Alexion ($100 million) and previous rounds of investment.

The idea behind the company’s technology is that messenger RNA, the chemical messenger that takes the genetic recipes encoded in DNA out of the cell’s nucleus and into another part of the cell where they can be turned into proteins, can themselves be used as drugs.

Figure. Source: http://modernatx.com/
Figure. Source: http://modernatx.com/

Figure. Source: http://modernatx.com/

To read the full article, please access at: http://www.forbes.com/sites/matthewherper/2015/01/05/moderna-therapeutics-raises-450-million-in-biggest-biotech-private-round-ever/

Disclaimer: This article does not reflect any personal views of the authors/editors

Previous articleKey protein in sucrose accumulation inside the taproot of sugar beet identified
Next articleNarendra Modi pushing India to get rid of red tape in Science
Scientist-entrepreneur-manager-journalist: -Co-founder, Author; Former Assistant Editor and Director, Biotechin.Asia, Biotech Media Pte. Ltd.; -Founder & CEO, SciGlo (www.sciglo.com); -Programme Management Officer, SBIC, A*STAR (former Research Fellow). --Sandhya graduated from University of Madras, India (B.Sc Microbiology and M.Sc Biotechnology) and received her Ph.D from the Nanyang Technological University, Singapore. She worked on oxidative stress in skin, skeletal, adipose tissue and cardiac muscle for a decade from 2006-2016. She is currently working as a Programme Management Officer handling projects and grants at Singapore Bioimaging Consortium (SBIC), Agency for Science, Technology and Research (A*STAR). Earlier to this she was a Research Fellow in the Fat Metabolism and Stem Cell Group at SBIC. Sandhya was also the Vice President and Publicity Chair of A*PECSS (A*STAR Post Doc Society) (2014-2016). Recently she founded a platform for scientists - SciGlo (www.sciglo.com) and is a startup mentor at Vertical VC (Finland). She is an ardent lover of science and enjoys globe trotting and good vegetarian food.